Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0114 in Amyotrophic Lateral Sclerosis
NCT06665165Phase 1Recruiting
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Active Treatment: AMX0114 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at Day 145. Started Apr 2025; status: recruiting.
02
Drugs
AMX0114
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06665165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665165.